Corrigendum: myelodysplastic syndrome/acute myeloid leukemia following the use of poly-adp ribose polymerase inhibitors: a real-world analysis of postmarketing surveillance data

HIGHLIGHTS

• who: PARP et al. from the Frontiers Media SA, SwitzerlandDepartment of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army have published the research: Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data, in the Journal: (JOURNAL)

SUMMARY

The corrected abstract appears below. In total, 16,710 and 11,937 PARP inhibitor AE reports were found in the FAERS and EV databases, of which 332 and 349 were associated with MDS and AML, respectively. The median latencies . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.